Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wouw, A J van der
Triple-B, NCT01898117 / 2013-001484-23: Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer	Active, not recruiting	2	304	Europe	Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab	The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG	Breast Cancer	12/24	12/30
SEQUEL-Breast, NCT05392608: SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer	Recruiting	2	130	Europe	Alpelisib 150 MG Oral Tablet [Piqray], Piqray, Fulvestrant, Faslodex	Borstkanker Onderzoek Groep, Novartis Pharma B.V., BOOG Study Center	Neoplasm, Breast, Congenital, Familial and Genetic Disorders	12/24	03/28